|
May 19
|
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
|
|
May 15
|
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
|
|
May 13
|
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
|
|
May 12
|
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025
|
|
Feb 17
|
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
|
|
Jan 10
|
Innate Pharma Announces Transformative Strategy to Accelerate Growth
|